Valuation: CorMedix Inc.

Market Cap 444M 398M 366M 331M 619M 42.15B 631M 4.36B 1.75B 22.17B 1.67B 1.63B 69.92B P/E 2026 *
11.5x
P/E 2027 * 100x
Enterprise Value 334M 300M 276M 250M 467M 31.76B 475M 3.29B 1.32B 16.71B 1.26B 1.23B 52.68B EV / Sales 2026 *
0.99x
EV / Sales 2027 * 1.03x
Free-Float
92.39%
Yield 2026 *
-
Yield 2027 * -
1 day-25.46%
1 week-27.45%
1 month-26.04%
3 months-24.37%
6 months-24.97%
Current year-51.03%
1 week 5.63
Extreme 5.63
8.35
1 month 5.63
Extreme 5.63
8.35
Current year 5.63
Extreme 5.63
12.29
1 year 5.63
Extreme 5.63
13.02
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 09/05/2022
Director of Finance/CFO 54 28/08/2025
Compliance Officer 66 11/12/2023
Director TitleAgeSince
Director/Board Member 67 05/08/2015
Chairman 81 02/08/2017
Director/Board Member 70 15/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Exercice

Director

97,818 0.1255%
29/08/26 Tax

Chief Financial Officer

-8,424 0.0108%
29/08/26 Tax

Compliance Officer

-8,424 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
-25.46%-27.45%-48.83%+63.65% 444M
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average -0.67%+2.56%+37.04%+82.47% 426.24B
Weighted average by Cap. +2.00%+6.59%+50.50%+100.43%

Financials

2026 *2027 *
Net sales 337M 302M 278M 252M 470M 32B 479M 3.31B 1.33B 16.84B 1.26B 1.24B 53.09B 289M 259M 238M 216M 404M 27.47B 411M 2.84B 1.14B 14.45B 1.09B 1.06B 45.56B
Net income 45.67M 40.9M 37.62M 34.09M 63.72M 4.34B 64.91M 449M 180M 2.28B 171M 168M 7.19B 5.33M 4.77M 4.39M 3.98M 7.44M 506M 7.58M 52.36M 21.02M 266M 20M 19.58M 839M
Net Debt -109M -98M -90.14M -81.68M -153M -10.39B -156M -1.07B -432M -5.47B -411M -402M -17.24B -147M -132M -121M -110M -206M -13.99B -209M -1.45B -581M -7.36B -553M -541M -23.21B
Projected Income Statement - Annual - CorMedix Inc.
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
30/10/26 US$5.695 -25.46% 7,017,384
29/10/26 US$7.640 -6.83% 1,887,156
28/10/26 US$8.200 +2.50% 1,158,418
27/10/26 US$8.000 +0.76% 1,002,475
26/10/26 US$7.940 +1.15% 1,130,293
Trader
Investor
Global
Quality
-
ESG MSCI
BB
MarketScreener Ratings - CorMedix Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.695USD
Average target price
15.33USD
Spread / Average Target
+169.24%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - CorMedix Inc.
  1. Stock Market
  2. Stocks
  3. CRMD Stock